MYL(SH:600993)2020-10-23 16:00Financial Performance - Net profit attributable to shareholders of the listed company was CNY 329,516,389.21, reflecting a growth of 12.36% year-on-year[17]. - Operating income for the period was CNY 1,735,357,252.18, a decrease of 9.76% compared to the same period last year[17]. - Basic earnings per share rose to CNY 0.76, an increase of 11.76% compared to the previous year[17]. - The weighted average return on equity was 12.23%, up by 0.03 percentage points from the previous year[17]. - Total operating revenue for Q3 2020 was approximately ¥754.29 million, an increase of 16.43% compared to ¥647.69 million in Q3 2019[51]. - Net profit for Q3 2020 reached ¥97.07 million, up 28.67% from ¥75.43 million in Q3 2019[54]. - Operating profit for Q3 2020 was ¥114.19 million, representing a 24.51% increase from ¥91.65 million in Q3 2019[54]. - Total profit for Q3 2020 was approximately ¥113.38 million, an increase of 24.00% from ¥91.51 million in Q3 2019[54]. - The company reported a total operating revenue of approximately ¥1.74 billion for the first three quarters of 2020, down 9.73% from ¥1.92 billion in the same period of 2019[51]. - The total profit for Q3 2020 was CNY 107.15 million, compared to CNY 88.78 million in Q3 2019, marking a growth of 20.7%[62]. Cash Flow - The net cash flow from operating activities increased by 147.92% to CNY 328,008,569.01 year-to-date[17]. - The company reported a net cash flow from operating activities of CNY 328,008,569.01, a 147.92% increase compared to CNY 132,302,654.41 in the same period last year[32]. - Cash flow from operating activities for the first three quarters of 2020 was CNY 423,258,181.46, a significant increase from CNY 103,108,414.76 in the same period of 2019, representing a growth of 310.5%[73]. - The company reported a net cash outflow from financing activities of -CNY 96,187,590.86, compared to -CNY 55,082,165.41 in the previous year, reflecting a decline in financing activities[75]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,809,766,292.58, an increase of 15.96% compared to the end of the previous year[17]. - The total number of shareholders at the end of the reporting period was 50,106, with the largest shareholder holding 29.27% of the shares[20]. - The company’s total equity reached $2,851,421,344.93, up from $2,634,955,808.27, reflecting a growth of approximately 8.2%[41]. - Current liabilities rose to $846,850,307.52, compared to $538,447,509.74, marking an increase of about 57.2%[41]. - The total liabilities increased to $958,344,947.65 from $650,487,442.87, marking a growth of about 47.2%[41]. - The company’s long-term equity investments increased to $750,666,111.69 from $685,184520.67, showing a growth of approximately 9.6%[46]. - The company’s goodwill increased by 260.63% to CNY 22,474,680.77 due to acquisitions of Jiangxi He Shi Mei Kang Pharmaceutical Co., Ltd. and Kanglide Pharmacy Chain (Hubei) Co., Ltd.[28]. Investments and Income - Investment income surged by 264.41% to CNY 72,703,281.95, driven by gains from stock disposals and increased returns from wealth management products[32]. - The company received government subsidies amounting to CNY 6,598,222.17 year-to-date, which are closely related to its normal business operations[19]. - The company reported a non-operating income of CNY 9,973,052.49 for the period from July to September[19]. - The company’s investment income for Q3 2020 was CNY 15.94 million, a significant increase from CNY 3.14 million in Q3 2019[62]. Operational Efficiency - The company executed new revenue standards, resulting in a 100% decrease in advance receipts, with contract liabilities reported at CNY 227,024,285.47[28]. - The company reported a decrease in sales costs to CNY 103.33 million in Q3 2020, up from CNY 83.92 million in Q3 2019, indicating improved cost management[62]. - Research and development expenses for Q3 2020 amounted to ¥13.01 million, a 29.93% increase from ¥10.01 million in Q3 2019[51]. - Research and development expenses increased to CNY 11.51 million in Q3 2020, representing a 35.8% rise from CNY 8.48 million in Q3 2019[62].